RelabotulinumtoxinA, a Ready-to-Use Formulation Neuromodulator Manufactured with PEARL™ Technology to Maintain High Biological and Specific Activity
Toxins · 09.10.2025 · 17 (10) · 501
DOI: 10.3390/toxins17100501 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxins, online erschienen am 09.10.2025. Verfasst von Ulf Ståhl und 8 weiteren Autor:innen. Beteiligte Einrichtung: Galderma, 752 28 Uppsala, Sweden. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Galderma.
Abstract (Originalsprache)
Most botulinum toxin A (BoNT-A) products for esthetic use require reconstitution before administration. Ready-to-use relabotulinumtoxinA is a liquid manufactured using Precipitation-free Extraction and Activity-preserving, Refined Liquid (PEARL™) Technology from a proprietary C. botulinum type A1 strain. We examined the in vitro characteristics of relabotulinumtoxinA. The specific BoNT-A1 potency remained consistent throughout drug substance manufacturing (1.9 × 108–2.2 × 108 LD50 mouse potency units/mg of BoNT-A1, four fractions sampled). Using glabellar line (GL) on-label doses, relabotulinumtoxinA liquid product was compared with powder onabotulinumtoxinA using the following: BoNT-A1 amount based on ELISA; specific enzyme activity based on SNAP-25 cleavage by a fluorescence resonance energy transfer-based assay (BoTest®); biological activity (binding, internalization, and SNAP-25 cleavage over time) using a cell-based assay. RelabotulinumtoxinA contained more BoNT-A1 per on-label GL dose (0.27 ng) than onabotulinumtoxinA (0.18 ng), had higher enzyme activity (53 vs. 29 BoTest® units) per GL dose, and had higher specific activity per pg BoNT-A, with onabotulinumtoxinA displaying 81% of the specific activity of relabotulinumtoxinA. In vitro, relabotulinumtoxinA demonstrated higher biological activity and earlier onset of SNAP-25-cleavage than onabotulinumtoxinA. PEARLTM Technology thus produces high-quality BoNT-A1 with high specific enzyme and biological activities, which may explain the clinical performance of relabotulinumtoxinA in Phase 3 clinical trials examining treatment of GLs and/or LCLs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Galderma, 752 28 Uppsala, Sweden.
- Department of Pharmaceutical Biosciences, Uppsala University, 751 24 Uppsala, Sweden.
- School of Medicine, Washington University, Saint Louis, MO 63110, USA.
- LUXURGERY, New York, NY 10022, USA.
- Smoothline, 80331 Munich, Germany.
- About Skin Dermatology, Greenwood Village, CO 80111, USA.
ORCID-Profile: Sachin M Shridharani, Keywan Taghetchian, Mark S Nestor
Förderung
- Galderma
Zitieren
APA
Ståhl, U., Lekholm, E., Hamnevik, E., Fredriksson, R., Shridharani, S. M., Taghetchian, K., Cohen, J. L., Nestor, M. S., & Liljegren Sundberg, Å. (2025). RelabotulinumtoxinA, a Ready-to-Use Formulation Neuromodulator Manufactured with PEARL™ Technology to Maintain High Biological and Specific Activity. Toxins, 17(10), 501. https://doi.org/10.3390/toxins17100501
Vancouver
Ståhl U, Lekholm E, Hamnevik E, Fredriksson R, Shridharani SM, Taghetchian K, et al. RelabotulinumtoxinA, a Ready-to-Use Formulation Neuromodulator Manufactured with PEARL™ Technology to Maintain High Biological and Specific Activity. Toxins. 2025;17(10):501. doi:10.3390/toxins17100501
BibTeX
@article{Sthl2025,
author = {Ståhl, Ulf and Lekholm, Emilia and Hamnevik, Emil and Fredriksson, Robert and Shridharani, Sachin M and Taghetchian, Keywan and Cohen, Joel L and Nestor, Mark S and Liljegren Sundberg, Åsa},
title = {RelabotulinumtoxinA, a Ready-to-Use Formulation Neuromodulator Manufactured with PEARL™ Technology to Maintain High Biological and Specific Activity},
journal = {Toxins},
year = {2025},
volume = {17},
number = {10},
pages = {501},
doi = {10.3390/toxins17100501}
}
EUVIMED